Johnson & Johnson (JNJ) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…
Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports…
Johnson & Johnson prepares to sell orthopedics unit for over $20 billion - Bloomberg…
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over…
Johnson & Johnson is investing more than $1 billion to build a new cell therapy plant in Montgomery County.…
The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology…
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility…
• Advanced manufacturing site will utilize cutting?edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines •…
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial…
Johnson & Johnson ordered to pay $250,000 in talc powder lawsuit…
Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…
Market Analysis by covering: Nasdaq 100, S&P 500, Johnson & Johnson, Meta Platforms Inc. Read s Market Analysis on…
This reliable dividend payer may be just what the doctor ordered.…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…
Johnson & Johnson is a picture of stability.…
Johnson & Johnson leads Zacks latest Analyst Blog as new research highlights earnings beats, growth drivers, and risks across major…
JNJs Q4 beat, Netflixs subscriber surge, and Arista Networks cloud demand highlight why these stocks headline todays top research reports.…
Morgan Stanleys price target implies that shares of Johnson & Johnson could rise another 17%.…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley:Die Analysten von Morgan Stanley stufen die Aktie von Johnson &…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Guggenheim Securities:Guggenheim-Analyst Vamil Divan habe das Kursziel für die Aktie von Johnson…
Frankfurt (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von XTB:Die Experten von XTB nehmen die Aktie der Johnson & Johnson (J&J) (ISIN:…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von TD Cowen:TD Cowen-Analyst Joshua Jennings habe das Kursziel für die Aktie von…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Goldman Sachs:Goldman-Sachs-Analyst Asad Haider habe das Kursziel für die Aktie von Johnson…
San Francisco (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Wells Fargo Advisors:Wells Fargo habe das Kursziel für die Aktie von Johnson…
Charlotte (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von BofA Securities:BofA-Analyst Jason Gerberry habe das Kursziel für die Aktie von Johnson &…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley:Morgan-Stanley-Analyst Terence Flynn habe das Kursziel für die Aktie von Johnson…
Wien (www.aktiencheck.de) - Netflix gab um 2% nach, nachdem die Geschäftszahlen nicht in allen Punkten überzeugen konnten, so die Analysten…
Johnson & Johnson had a strong year.…
By John Vandermosten, CFANASDAQ:MDAIREAD THE FULL MDAI RESEARCH REPORTIt has now been approximately seven months since Spectral AI, Inc. (NASDAQ:MDAI)…
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in…
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +1.05% and +1.84%, respectively, for the quarter ended December 2025.…
…
Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)s Spravato (esketamine nasal spray) could provide a meaningful...…
Johnson & Johnson also reported a fourth-quarter profit ahead of expectations, buoyed by strong sales of the blood cancer therapy…
Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026…
In a victory for thousands of women suing Johnson & Johnson over claims that the companys baby powder and…
Johnson & Johnson (JNJ) just made a move that investors have been waiting years to see. The healthcare heavyweight submitted…
Netflix, Intel and Johnson & Johnson headline Zacks Investment Ideas as key earnings reports approach amid steady estimates.…
The fourth-quarter U.S. earnings season heats up, with reports due from high-profile companies including Netflix (NFLX), Johnson & Johnson (JNJ),…
Stocks beyond tech are getting their day in the sun. Stocks like Morgan Stanley, Johnson & Johnson, and Caterpillar are…
Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.…
…
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein:Bernstein-Analyst Lee Hambright habe das Kursziel für die Aktie von…
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trumps administration to cut drug…
JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into…
Der Pharmakonzern Bayer wirft Pfizer, Biontech und Moderna vor, bei ihren Covid-19-Impfstoffen eine patentierte mRNA-Technologie der Bayer-Tochter Monsanto genutzt zu…
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from…
London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Barclays:Barclays habe das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN:…
New York (www.aktiencheck.de) - Apogee Therapeutics-Aktienanalyse von BTIG:Die Analysten von BTIG haben das "buy"-Rating für die Aktie von Apogee Therapeutics…